ArriVent Announces a Multi-Target ADC Collaboration with Alphamab [Yahoo! Finance]
ArriVent BioPharma, Inc. (AVBP)
Company Research
Source: Yahoo! Finance
Upfront and milestone payments to Alphamab worth up to $615.5 million for potential ADCs SUZHOU, China and NEWTOWN SQUARE, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. , (“ArriVent”) a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the Company has entered into a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Alphamab”), a wholly owned subsidiary of Alphamab Oncology, to discover, develop and commercialize novel antibody drug conjugates (“ADCs”) for the treatment of cancers. “This exciting collaboration strengthens and complements our pipeline with the potential to add multiple innovative new ADC programs and exemplifies our strategic model of identifying and developing potential first-and best-in-class product candidates from across the globe,” said Bing Yao, Chairman and Chief Executive Officer of ArriVent. “We look forward to complementing
Show less
Read more
Impact Snapshot
Event Time:
AVBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVBP alerts
High impacting ArriVent BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
AVBP
News
- Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476M [Seeking Alpha]Seeking Alpha
- ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.MarketBeat
- Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products [Yahoo! Finance]Yahoo! Finance
- ArriVent Announces a Multi-Target ADC Collaboration with AlphamabGlobeNewswire
- ArriVent Appoints John Hohneker, M.D., to its Board of DirectorsGlobeNewswire
AVBP
Sec Filings
- 6/5/24 - Form 8-K
- 5/20/24 - Form 4
- 5/20/24 - Form 3
- AVBP's page on the SEC website